Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
Guardant Health (Nasdaq: GH) has partnered with the Abu Dhabi Public Health Center to implement a non-invasive blood-based colorectal cancer screening program using their Shield™ test. The agreement, established through Hikma Pharmaceuticals PLC, will be managed by the M42 healthcare system.
The initiative aims to address the significant challenge of colorectal cancer in Abu Dhabi, where it ranks as the third most common cancer type, with 63% of cases diagnosed at late stages. The Shield test will be integrated into the ADPHC's IFHAS comprehensive health screening program, available across major healthcare facilities in Abu Dhabi, Al Ain, and the Al Dhafra region.
The program targets to screen approximately 10,000 people in its first year, offering a more comfortable screening alternative to increase participation rates and improve early detection outcomes.
Guardant Health (Nasdaq: GH) ha collaborato con il Centro per la Salute Pubblica di Abu Dhabi per implementare un programma di screening del cancro colorettale non invasivo basato su un test del sangue, utilizzando il loro test Shield™. L'accordo, stabilito attraverso Hikma Pharmaceuticals PLC, sarà gestito dal sistema sanitario M42.
L'iniziativa mira ad affrontare la significativa sfida del cancro colorettale ad Abu Dhabi, dove è il terzo tipo di cancro più comune, con il 63% dei casi diagnosticati in fasi avanzate. Il test Shield sarà integrato nel programma di screening sanitario completo IFHAS dell'ADPHC, disponibile nelle principali strutture sanitarie di Abu Dhabi, Al Ain e nella regione di Al Dhafra.
Il programma prevede di screeningare circa 10.000 persone nel suo primo anno, offrendo un'alternativa di screening più comoda per aumentare i tassi di partecipazione e migliorare i risultati della diagnosi precoce.
Guardant Health (Nasdaq: GH) se ha asociado con el Centro de Salud Pública de Abu Dhabi para implementar un programa de detección del cáncer colorrectal no invasivo basado en sangre utilizando su prueba Shield™. El acuerdo, establecido a través de Hikma Pharmaceuticals PLC, será gestionado por el sistema de salud M42.
La iniciativa tiene como objetivo abordar el importante desafío del cáncer colorrectal en Abu Dhabi, donde ocupa el tercer lugar como tipo de cáncer más común, con un 63% de los casos diagnosticados en etapas avanzadas. La prueba Shield se integrará en el programa integral de salud IFHAS del ADPHC, disponible en las principales instalaciones sanitarias de Abu Dhabi, Al Ain y la región de Al Dhafra.
El programa tiene como objetivo realizar exámenes a aproximadamente 10,000 personas en su primer año, ofreciendo una alternativa de detección más cómoda para aumentar las tasas de participación y mejorar los resultados de la detección temprana.
가드란트 헬스 (Nasdaq: GH)가 아부다비 공공보건센터와 협력하여 쉴드™ 테스트를 이용한 비침습적 혈액 기반 대장암 검진 프로그램을 구현하고 있습니다. 이 계약은 Hikma Pharmaceuticals PLC를 통해 체결되었으며, M42 의료 시스템에 의해 관리됩니다.
이 이니셔티브는 아부다비에서 대장암이 세 번째로 흔한 암 유형으로 자리 잡고 있으며, 63%의 경우가 말기 단계에서 진단되는 중대한 문제를 해결하는 것을 목적으로 합니다. 쉴드 테스트는 ADPHC의 포괄적인 건강 검진 프로그램인 IFHAS에 통합될 예정이며, 아부다비, 알 아인 및 알 다프라 지역의 주요 의료 시설에서 이용할 수 있습니다.
이 프로그램은 첫해에 약 10,000명을 선별 검사할 계획이며, 더 편안한 검진 대안을 제공하여 참여율을 높이고 조기 발견 결과를 개선하는 데 기여하고자 합니다.
Guardant Health (Nasdaq: GH) s'est associé au Centre de santé publique d'Abu Dhabi pour mettre en œuvre un programme de dépistage du cancer colorectal non invasif basé sur un test sanguin grâce à leur test Shield™. L'accord, établi par l'intermédiaire de Hikma Pharmaceuticals PLC, sera géré par le système de santé M42.
Cet initiative vise à relever le défi important du cancer colorectal à Abu Dhabi, où il se classe au troisième rang des types de cancer les plus courants, avec 63 % des cas diagnostiqués à un stade avancé. Le test Shield sera intégré au programme de dépistage sanitaire complet IFHAS de l'ADPHC, disponible dans les principales installations de santé d'Abu Dhabi, Al Ain et la région d'Al Dhafra.
Le programme vise à dépister environ 10 000 personnes au cours de sa première année, offrant une alternative de dépistage plus confortable pour augmenter les taux de participation et améliorer les résultats de détection précoce.
Guardant Health (Nasdaq: GH) hat sich mit dem Abu Dhabi Public Health Center zusammengeschlossen, um ein nicht-invasives, blutbasierendes Screening-Programm zur Erkennung von Darmkrebs mit ihrem Shield™-Test zu implementieren. Das durch Hikma Pharmaceuticals PLC etablierte Abkommen wird vom Gesundheitsnetzwerk M42 verwaltet.
Das Projekt zielt darauf ab, die erhebliche Herausforderung von Darmkrebs in Abu Dhabi anzugehen, wo dieser Krebs an dritter Stelle der häufigsten Krebsarten steht, und 63% der Fälle erst in einem späten Stadium diagnostiziert werden. Der Shield-Test wird in das umfassende Gesundheits-Screening-Programm IFHAS des ADPHC integriert, das in den wichtigsten Gesundheitseinrichtungen in Abu Dhabi, Al Ain und der Region Al Dhafra verfügbar sein wird.
Das Programm plant, im ersten Jahr etwa 10.000 Personen zu testen und bietet eine komfortablere Screening-Alternative, um die Beteiligungsraten zu erhöhen und die Ergebnisse der frühzeitigen Erkennung zu verbessern.
- Secured major contract with Abu Dhabi Public Health Center for colorectal cancer screening
- Program targets approximately 10,000 screenings in first year
- Strategic expansion into Middle East market through partnership with Hikma Pharmaceuticals
- None.
Insights
The selection of Guardant Health's Shield test by Abu Dhabi's Department of Health marks a strategic milestone in the company's international commercialization efforts. This agreement demonstrates several key advantages:
- Market Validation: The adoption by a major Middle Eastern healthcare system validates Shield's competitive position against traditional screening methods.
- Revenue Potential: With 10,000 initial screenings targeted, this program could generate significant recurring revenue, considering the test's premium positioning and the wealthy UAE market.
- Expansion Template: Success in Abu Dhabi could serve as a blueprint for similar programs across the Middle East and North Africa region, where Hikma Pharmaceuticals' established presence can accelerate market entry.
- Clinical Impact: Addressing the 63% late-stage diagnosis rate in Abu Dhabi positions Shield as a critical tool for improving healthcare outcomes, potentially leading to broader adoption.
The partnership with Hikma Pharmaceuticals and M42 healthcare system provides Guardant with established distribution channels and local market expertise, reducing market entry barriers and accelerating adoption. This development could serve as a catalyst for similar agreements in other regions where traditional screening methods face adherence challenges.
Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer
Colorectal cancer is the third most common type of cancer in
The Shield test will be provided as part of the ADPHC’s IFHAS comprehensive health screening program and will be available at major healthcare facilities operated by Ambulatory Healthcare Services and M42 sites across
“Early detection of colorectal cancer can dramatically improve survival rates,” said AmirAli Talasaz, Guardant Health co-CEO. “This new population screening program by the Department of Health in
The blood-based colorectal cancer screening program is expected to screen approximately 10,000 people across
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
References
- Abu Dhabi Public Health Centre press release: https://www.wam.ae/en/article/b6dgstz-abu-dhabi-introduces-non-invasive-liquid-biopsy
- BMC Public Health. 2023 Oct 16;23:2015. doi: 10.1186/s12889-023-16951-7
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130054040/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What is the target screening volume for Guardant Health's Shield test in Abu Dhabi?
Where will Guardant Health's Shield test be available in Abu Dhabi?
What is the current late-stage diagnosis rate for colorectal cancer in Abu Dhabi?
Which healthcare system will administer Guardant Health's Shield test program in Abu Dhabi?
How is Guardant Health (GH) entering the Middle Eastern market for the Shield test?
